Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NaviPort 3D emerges from BrainLAB, Ziehm pact

This article was originally published in Clinica

Executive Summary

Surgical navigation technology specialist BrainLAB and mobile imaging systems firm Ziehm Imaging have developed the Ziehm NaviPort 3D interface, as part of an ongoing collaboration between the two German companies. The interface allows the combined use of Ziehm's mobile 3D C-arms and BrainLAB's computer-assisted Fluoro-3D-navigation system, thereby enabling surgical operations to be more precise, less invasive and faster, said Nuremberg-based Ziehm. The company added that the combination of the two technologies replaces the need for post-operative CT scans, thus reducing the patient's exposure to radiation. Feldkirchen-based BrainLAB and Ziehm agreed to integrate their technologies to develop 3D intra-operative imaging solutions in October 2007 (see Clinica No 1276, p 12).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT043554

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel